COHERUS BIOSCIENCES
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.
COHERUS BIOSCIENCES
Industry:
Biotechnology Health Care Manufacturing Medical Therapeutics
Founded:
2007-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.coherus.com
Total Employee:
251+
Status:
Active
Contact:
(650) 649-3530
Total Funding:
602.51 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Viragen
Viragen researches, develops, manufactures and commercializes therapeutic proteins for the treatment of cancers and viral diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-02-12 | InteKrin | InteKrin acquired by Coherus Biosciences | 5 M USD |
Investors List
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Coherus Biosciences
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences investment in Post-IPO Equity - Coherus Biosciences
Lord Abbett
Lord Abbett investment in Post-IPO Equity - Coherus Biosciences
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Coherus Biosciences
Kohlberg Kravis Roberts
Kohlberg Kravis Roberts investment in Series C - Coherus Biosciences
KMG Capital Partners
KMG Capital Partners investment in Series C - Coherus Biosciences
Viva Capital Advisors
Viva Capital Advisors investment in Series C - Coherus Biosciences
Sofinnova Investments
Sofinnova Investments investment in Series C - Coherus Biosciences
Eight Roads Ventures
Eight Roads Ventures investment in Series C - Coherus Biosciences
Rock Springs Capital
Rock Springs Capital investment in Series C - Coherus Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-15 | Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer |
| 2021-12-17 | Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer |
Official Site Inspections
http://www.coherus.com Semrush global rank: 2.83 M Semrush visits lastest month: 5.73 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Coherus Biosciences"
Coherus | Innovative Immunotherapies for Cancer | About
Every member of the Coherus team is dedicated, motivated, and passionate about improving patient care. Our colleagues are experts in immunology, analytical and process sciences, biologic process development, manufacturing …See details»
Corporate Overview - Coherus BioSciences, Inc.
Coherus’ earlier-stage immuno-oncology pipeline includes CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways. Coherus markets LOQTORZI™ …See details»
Coherus | Novel Immuno-Oncology Medicines | Our …
When I joined Coherus in June 2021 as the Director and head of QC stability, I was inspired by the company mission to bring lifesaving therapeutics to patients at reduced costs without compromising quality. ... We create long-term value …See details»
Denny Lanfear - Founder, President, and Chief Executive Officer ...
Seasoned Biotech Executive | Chairman, Founder & CEO at Coherus · Denny Lanfear, a veteran biotech executive, has significantly influenced the biotech landscape through his tenure with …See details»
Coherus Biosciences - Crunchbase Company Profile & Funding
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic …See details»
Coherus BioSciences - LinkedIn
Coherus BioSciences | 36,123 followers on LinkedIn. We are in the business of extending life for patients. | Coherus is a commercial-stage biopharmaceutical company focused on the research ...See details»
Coherus Biosciences Inc - AnnualReports.com
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar …See details»
Coherus BioSciences - Org Chart, Teams, Culture & Jobs - The Org
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in …See details»
Coherus BioSciences Inc: Overview - GlobalData
Coherus BioSciences Inc (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development, and commercialization of innovative immunotherapies to …See details»
Coherus to Acquire Surface Oncology - Coherus BioSciences, Inc.
Jun 16, 2023 Information about the directors and executive officers of Coherus, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Coherus’ proxy statement for its 2023 Annual General Meeting, which was filed with the SEC on April 17, 2023, the Annual Report on Form 10-K for the year ended December 31, 2022 filed …See details»
Member Spotlight: Coherus BioSciences - SAMS
Apr 25, 2022 Coherus BioSciences, one of our founding member companies, is a commercial-stage biopharmaceutical company focused on the research, development, and …See details»
Coherus BioSciences, Inc. | Coherus BioSciences Reports Third …
Nov 6, 2024 – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA ® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming …See details»
Coherus BioSciences, Inc. | Coherus Launches YUSIMRY™, a …
REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now …See details»
Coherus | Novel Immuno-Oncology Treatments | Leadership
For over a decade, the Coherus team has successfully launched multiple drugs. Our drug discovery, development and commercialization experience combined with our relentless …See details»
Coherus BioSciences - Company Profile - Employbl
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in …See details»
Patient Advocacy - Coherus BioSciences
I have been asked by a nonprofit organization to co-lead a support group for caregivers and patients. I am so happy for the opportunity to volunteer and share what I have learned with …See details»
Coherus Biosciences - Silicon Valley Journals
Coherus Biosciences is a biopharmaceutical company that develops and commercializes high-quality biosimilar therapeutics. The company’s mission is to increase access to biologic …See details»
Coherus BioSciences, Inc. | Coherus Completes Strategic …
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company; NASDAQ: CHRS) today announced the completion of the …See details»
Coherus Completes Strategic Transformation with Successful …
Apr 14, 2025 Coherus BioSciences, Inc. – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –See details»
Coherus Completes Strategic Transformation with Successful …
Apr 14, 2025 Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI ® (toripalimab-tpzi), growing …See details»